Bifogade filer
ENG Xspray Pharma Q1 2022
Kurs & Likviditet
Prenumeration
Du har en aktiv prenumeration.
Prenumerera på pressmeddelanden från Xspray Pharma AB via email.
Du prenumererar på följande språk.
Välj vilka språk du vill prenumerera på.
Modular Finance AB kommer att hantera vissa av dina personuppgifter om du väljer att prenumerera. Mer information om vår personuppgiftshantering finns här.
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Small Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
2022-05-06 08:30:00
First Quarter 2022 (January 1 - March 31), Group
- Net sales amounted to SEK 0 thousand (0)
- Loss before tax amounted to SEK -18,934 thousand (-13,912)
- Earnings per share before dilution amounted to SEK -0.92 (-0.73)
- Cash flow from operating activities amounted to SEK -27,613 thousand (-11,971)
- Cash flow from investing activities amounted to SEK -47,541 thousand (-25,188)
- Cash and cash equivalents at the end of the period amount-ed to SEK 196,212 thousand (292,265)
Amounts in parentheses refer to the year-earlier period.
Significant events during the quarter
- In January, the FDA announced that the application for market approval of Dasynoc had been accepted for a full review.
- In February, the company announced that it had hired Anna-Karin Ekberg as Global Head of Marketing and Sales. Anna-Karin took office on March 15, 2022 and is now part of the company’s management group.
- In February, it was announced that Bristol Myers Squibb had filed a lawsuit against Xspray Pharma in the US claiming pa-tent infringement in relation to the submission of Xspray Pharma’s 505(b)(2) New Drug Application to the FDA.
“Xspray Pharma is in an intense period, with a focus on building up the company, commercialization, the project portfolio, and production capacity. It is intensive, rewarding work for all of us,” says Per Andersson, CEO.